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a b s t r a c t
It has been long assumed that DNA damage is induced in a linear manner with respect to the dose of a
direct acting genotoxin. Thus, it is implied that direct acting genotoxic agents induceDNAdamage at even
the lowest of concentrations and that no “safe” dose range exists. The linear (non-threshold) paradigm
has led to the one-hitmodel being developed. This “one hit” scenario can be interpreted such that a single
DNA damaging event in a cell has the capability to induce a single point mutation in that cell which could
(if positioned in a key growth controlling gene) lead to increased proliferation, leading ultimately to the
formation of a tumour.
There are many groups (including our own) who, for a decade or more, have argued, that low dose
exposures to direct acting genotoxins may be tolerated by cells through homeostatic mechanisms such
as DNA repair. This argument stems from the existence of evolutionary adaptive mechanisms that allow
organisms toadapt to low levels of exogenous sourcesof genotoxins.Wehavebeenparticularly interested
in the genotoxic effects of known mutagens at low dose exposures in human cells and have identiﬁed for
the ﬁrst time, in vitro genotoxic thresholds for several mutagenic alkylating agents (Doak et al., 2007).
Our working hypothesis is that DNA repair is primarily responsible for these thresholded effects at low
doses by removing low levels of DNA damage but becoming saturated at higher doses. We are currently
assessing the roles of base excision repair (BER) and methylguanine-DNA methyltransferase (MGMT)
for roles in the identiﬁed thresholds (Doak et al., 2008). This research area is currently important as it
assesses whether “safe” exposure levels to mutagenic chemicals can exist and allows risk assessment
using appropriate safety factors to deﬁne such exposure levels. Given human variation, the mechanistic
basis for genotoxic thresholds (e.g. DNA repair) has to bewell deﬁned in order that susceptible individuals
are considered.
In terms of industrial exposures to known mutagens, knowing the dose relationships and protective
mechanisms involved, offers the possibility of screening workers for susceptibility to mutation through
examining DNA repair gene polymorphisms. Hence, thresholds may exist for certain mutagens, but there
will undoubtedly be human subpopulations who are more at risk from low dose exposures than others
and who should not be exposed, if possible. By studying polymorphisms in DNA repair genes, susceptible
individuals may be identiﬁed, and additional safety factors appropriately targeted to these populations.
© 2009 Published by Elsevier Ireland Ltd.
1. Genetic toxicology19
Genetic toxicology, which evolved in the latter half of the twen-20
tieth century, is involved in the study of DNA damage andmutation21
and its impact on human health. Genotoxicity describes many22
different DNA endpoints including DNA adduct formation, point23
mutation, chromosome breakage and chromosome copy number24
changes. From its inception, genotoxicity has been used as a sur-25
Abbreviations: MMS, methyl methanesulphonate; MNU, methyl nitrosourea;
EMS, ethyl methanesulphonate; BER, base excision repair; MGMT, methyl guanine
DNA methyl transferase.
∗ Corresponding author. Tel.: +44 1792 602512; fax: +44 1792 295048.
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rogate for cancer, as genotoxins are almost always carcinogens 26
and cancer has traditionally been seen as a genetic disease char- 27
acterised by acquired DNA mutations in growth controlling genes. 28
Consequently, assessment of the genotoxicity of new chemicals 29
is seen as a key regulatory requirement to minimise any delete- 30
rious effects that may be produced through genotoxic exposures 31
within human populations. As part of the safety assessment of 32
newchemicals (pharmaceuticals, consumer products, etc.), a tiered 33
approach to genotoxicity testing is currently recommended. This 34
tiered approach is well described by the Committee on Mutagenic- 35
ity (COM) guidance (Guidance on a Strategy for testing of chemicals 36
for Mutagenicity, 2000) and involves all chemicals entering so- 37
called stage 1 tests where DNA damage induction is assessed in 38
cells cultured in the laboratory. Negative results in these tests reas- 39
sure the manufacturer that DNA damage is unlikely to be induced 40
0300-483X/$ – see front matter © 2009 Published by Elsevier Ireland Ltd.
doi:10.1016/j.tox.2009.11.016
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Fig. 1. Dose–responses induced by genotoxic agents. Theoretical mutagenic
dose–responses for genotoxic agents are displayed. Linear response (solid line)
implies no safe lowdose. Note the line does not go through the origin, as background
mutation levels are detectable in vitro and in vivo. The shaded area represents the
background level (historial background ranges can deﬁne this region). Thresholded
responses are depicted by the dotted line in the low dose range. At the low dose
region no increase over background mutation level is seen, followed by a critical
dose range where mutagenic responses are observed. The boundary between no
effect and effect is represented by the no observable effect level (NOEL) and the low-
est observable effect level (LOEL), and the threshold dose is statistically calculated
where the slope of the graph ﬁrst increases signiﬁcantly.
by that agent. Stage 2 tests are employed for positives from stage 141
tests and for compounds with medium to high exposure potentials42
and are carried out in animals. The stage 2 tests are designed to43
overcome problems with false positive results which can occur in44
stage 1 tests and also to more rigorously assess the risks to human45
health.46
2. Linear dose–response relationships for genotoxins47
In genetic toxicology a linear dose–response relationship has48
long been assumed to apply for direct acting genotoxic agents49
(Henderson et al., 2000). Fig. 1 displays the different theoretical50
dose–response relationships for genotoxins (linear and thresh-51
olded). In the linear model, DNA damage induction is believed to52
be directly proportional to dose; leading to the implication that53
there are no genotoxic doses, however low, devoid of a ﬁnite risk54
of genetic damage and hence cancer. This linear model has been55
implemented partly because of early experimental evidence and56
partly due to the precautionary principle. This linear concept has57
been controversial and has recently been challenged by ourselves58
and others, as it assumes a binary situation where chemicals are59
either genotoxic or not, but does not account for the effect of dose.60
As pointed out by Paracelsus in the 16th Century, “only the dose61
permits something not to be poisonous”. In this context it is inter-62
esting to note that carcinogenesis has recently been shown to be63
induced in a non-linear manner with low doses of genotoxic agents64
failing to drive cancer formation in trout even when large numbers65
of animals were examined (>40,000) (Bailey et al., 2009).66
In the case of indirect genotoxins which have non-DNA tar-67
gets (aneuploidy inducing agents and agents interacting with68
DNA modifying enzymes), thresholds have now been accepted69
(Elhajouji et al., 1997; Lynch et al., 2003). Hence, this demon-Q270
strates the usefulness of solid experimental evidence in altering71
paradigms. However, for direct acting genotoxins, linear models72
are still assumed to apply. Recently, the role of dose inmutagenicity73
testing in general has been a major issue in the ﬁeld and inappro-74
priately high doses have been suggested to be responsible formany75
of the false positive results in stage 1 tests (Kirkland et al., 2007).76
High doses of chemicals have traditionally been used to ensure that77
DNA damaging effects are identiﬁed in the available tests (due to78
test sensitivity constraints) andbecause ithaswidelybeenassumed79
that the effects are induced in a linear manner, this is then extrapo-80
latedback to the lowdose region. Therefore, if ahighdose ispositive81
for genotoxicity, then under this linear paradigm, a low dose will 82
also be positive. Hence, the implications emanating from the lin- 83
ear model for genotoxins can be wide reaching and can impact 84
scientiﬁcally and economically on the availability and use of cer- 85
tain chemicals. As the linear model is currently being challenged, 86
this paradigm is subject to change which may affect future regu- 87
latory testing and allow some previously unavailable chemicals to 88
be licensed for use in the future. 89
3. Theoretical arguments against a linear response for 90
genotoxins 91
The main argument against a linear dose–response for geno- 92
toxins is the presence of natural defences which have evolved 93
to cope with our daily exposure to genotoxins. Humans are con- 94
stantly exposed to genotoxic substances like cytosolic oxidative 95
agents, dietary amines, inhaled hydrocarbons and many others. 96
Low level exposures to these genotoxins have occurred through- 97
out evolutionary time and have led to the development of efﬁcient 98
homeostatic defences to protect organisms against the deleteri- 99
ous mutagenic consequences. DNA repair is one such homeostatic 100
defence mechanism that may impact on the consequences of 101
genotoxin exposure. Indeed, even simple bacteria have intricate 102
defences (like DNA repair) against genotoxins. As multicellular 103
organisms, humans have several tiers of protection against DNA 104
damage including, but not restricted to: 105
1. Epithelial barriers to genotoxin entry. 106
2. Detoxiﬁcation processes leading to excretion of water soluble 107
genotoxins. 108
3. Compartmentalisation of tissues leading to reduced access for 109
genotoxins. 110
4. Cellular and nuclear membranes reducing access of genotoxins 111
to the nucleus. 112
5. DNA repair to remove damaged DNA sequences. 113
6. DNA redundancy (<1% gives are thought to code for proteins). 114
7. Apoptosis/autophagy/anoikis to remove damaged cells. 115
Hence, it is theoretically difﬁcult for genotoxins to cause DNA 116
damage in a manner proportional only to dose. This is due in part 117
to the failure of the genotoxin to readily access the DNA of a target 118
tissue. Even in a simple cell culture system, it is unlikely that true 119
linearity will be seen due to extracellular and intracellular interac- 120
tions between the genotoxin and non-DNA biomolecules, as well 121
as membrane-based exclusion. Furthermore, once in the nucleus, 122
genotoxins must overcome the homeostatic protection afforded by 123
DNA repair to produce permanent DNA sequence alterations. 124
DNA repair has over recent decades been shown to function in 125
a complex and, in some cases, in an inducible manner to control 126
the genetic stability of the host cell’s genome. Several overlap- 127
pingDNA repair pathways existwhich are responsible for repairing 128
speciﬁc DNA damage types (e.g. base excision repair, nucleotide 129
excision repair, homologous recombination,mismatch repair, etc.). 130
DNA repair has been well reviewed elsewhere (Hoeijmakers, 2009; Q3 131
Riches et al., 2008). Hence, it is likely that DNA repair will impact 132
directly on the linearity of genotoxic dose–responses by remov- 133
ing DNA damage, particularly at low doses. At higher doses DNA 134
repair may be saturated and hence not be able to remove newly 135
damaged DNA bases. There is some evidence that DNA adduct for- 136
mation accrues in a linear fashion (Perera, 1988; Zito, 2001), but it 137
is likely that ﬁxed mutations (point mutations, chromosome dam- 138
age) will not. One complication with the DNA adduct data is that 139
although the assays for their detection are very sensitive (10−8), 140
they do not deﬁne where in the genome the adducts are present. 141
Given that cells have evolved efﬁcient measures to keep gene cod- 142
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Fig. 2. Example of dose–response threshold for EMS induced micronucleus fre-
quency (chromosome damage: line graph). Columns depict binucleate frequency
as a measure of toxicity and clearly show no toxicity in this dose range. Here AHH1
cells were treated with increasing doses of EMS and especially large numbers of
cells (up to 10,000 per dose) were assessed for micronuclei to increase the sensitiv-
ity of the assay and allow the dose–response to be truly examined. This data is taken
from that published previously by ourselves (Doak et al., 2007). EMS clearly does not
induce chromosome breakage (line graph) at low dose levels (<1.3g/ml), whereas
at doses higher than this, chromosome damage is seen to increase. Simple statistical
tests (one-way ANOVA with Dunnett’s post hoc test) showed that 1.4g/ml was the
ﬁrst dose showing signiﬁcant genotoxicity, but more complex statistical modelling
has identiﬁed 1.06g/ml as the point of inﬂection in the dose–response and hence
the threshold dose (Johnson et al., 2009).
ing sequences damage free at the expense of non-coding regions143
(Hanawalt, 1994), it is not possible to currently say if DNA adductsQ4144
accrue in a linear fashion in the coding sequences which form the145
basis for most genotoxicity tests.146
4. Experimental evidence for genotoxic thresholds147
Attempts to deﬁne genotoxic thresholds have mainly centred148
on using direct acting DNA damaging genotoxins. This is in con-149
trast to genotoxins requiring metabolic activation, due to the150
confounding effects of such activation, which may itself impose151
a non-linear dose–response dependent upon the efﬁciency of the152
metabolic enzyme(s) involved. If genotoxic thresholdsareaccepted153
for direct acting genotoxic agents, they will certainly exist for154
agents requiringmetabolic activation, and themechanism involved155
in the threshold regionmay additionally involve, for example, P450156
enzyme efﬁciency. Our research group was the ﬁrst to compre-157
hensively demonstrate that direct acting genotoxins could exhibit158
thresholds for mutation induction and chromosome breakage in159
vitro (Doak et al., 2007). These data have led to a paradigm shift160
in genetic toxicology and has been subject to debate at the highest161
levels concerning how to modulate safety assessment procedures162
to account for potential genotoxic thresholds. It is of paramount163
importance that thedatagenerated to investigategenotoxic thresh-164
olds should be appropriately analysed by extensive statistical165
modelling and that abundant high quality data is solely generated166
for this purpose. Furthermore, themechanistic basis for any thresh-167
olded effects requires some thought (and some investigation) in168
order to provide a plausible explanation of the results.169
We demonstrated that the well known genotoxic and car-170
cinogenic alkylating agents EMS and MMS displayed genotoxic171
thresholds, whereby low dose exposures showed no increase in172
DNA damage above background levels evident in untreated cells173
(Fig. 2 shows the chromosome damage data for EMS in vitro as174
an example). A statistical modelling approach has recently con-175
ﬁrmed the “hockey stick” shape to the curves for EMS and MMS176
and highlights the critical threshold doses (Johnson et al., 2009).177
Our data were accompanied by supporting DNA adduct data show-178
ing that DNA adduct formation increased linearly across the same 179
dose range, thus conﬁrming that adequate nuclear exposure was 180
achieved (Swenberg et al., 2008). The identiﬁcation of DNA adducts 181
at doses where no mutations were found may suggest that DNA 182
adducts were present in the genome but not perhaps in the locus 183
used for mutational analysis (the hprt gene). Crucially, this in vitro 184
threshold data has now been elegantly conﬁrmed in vivo for EMS 185
using the mouse bone-marrow micronucleus test and point muta- 186
tion at the lacZ locus (Gocke et al., 2009). Furthermore, through 187
comprehensive pharmacokinetic studies, a cross-species analy- 188
sis has allowed extrapolation from the genotoxic threshold dose 189
observed in the mice to a corresponding threshold in humans. 190
Hence, safe exposure levels for EMShave been identiﬁed, providing 191
a precedent for future safety assessment for genotoxic carcinogens 192
with thresholded dose–response curves. 193
Interestingly, the mouse chromosome damage data showed 194
a potential hormetic effect for micronucleus induction in vivo, 195
suggesting homeostatic mechanisms were induced which also 196
removed some endogenous DNA damage (Gocke et al., 2009). 197
Hormetic effects have never before been observed in genetic tox- 198
icology and reinforce the concept that organisms can tolerate low 199
levels of DNA damage. The acceptance of hormetic effects in the 200
low dose region of genotoxin exposure may lead to a signiﬁcant 201
rethink for regulatory toxicology (Calabrese and Baldwin, 2003). 202
Hormetic effects in genotoxicity further highlight the roles for 203
inducible homeostatic mechanisms, like DNA repair in low dose 204
exposure situations. 205
It is now possible to say with some conﬁdence that genotoxic 206
thresholds exist both in vitro and in vivo for some chemicals at 207
least. How widespread these genotoxic thresholds will prove to 208
be, can only be answered through further investigation. There- 209
fore, genotoxic carcinogens like EMS and MMS can display dose 210
ranges where there is no elevation of genetic damage above back- 211
ground levels and thus safe exposures can exist for these chemicals. 212
This has important implications for regulating the exposure lev- 213
els to genotoxic carcinogens. Whilst providing fascinating insight 214
into how genotoxins interact with DNA at low levels, this data 215
does not tell us how cells tolerate low levels of the alkylating 216
agents. These fundamentalmechanisms of action underlying geno- 217
toxic thresholds have been the focus of our attention for the past 218
2 years. We showed recently that the DNA repair protein O6- 219
methylguanine-DNA methyltransferase (MGMT), which removes 220
the O6G alkyl lesion from DNA, was up-regulated by MMS at doses 221
below the threshold, but not above it, suggesting that MGMT might 222
be involved in the threshold by selectively removing the DNA 223
adducts at low doses but becoming saturated (or repressed) at 224
higher doses (Doak et al., 2008). Previous genotoxic studies in 225
vitro have highlighted a potential role for MGMT in altering the 226
shape of dose–responses. In both bacterial and mammalian cells, 227
MGMT knockouts have been shown to alter the shape of muta- 228
tional dose–responses to a more linear shape in contrast to the 229
sublinear shapes in the wild type cells (Rebeck and Samson, 1991; 230
Kaina et al., 1998; Sofuni et al., 2000). As the alkylating agents EMS 231
and MMS also induce high levels of N7Guanine which is repaired 232
by base excision repair (BER), the BER glycosylase N-methylpurine 233
DNAglycosylase (MPG) is also likely to be involved in the genotoxic 234
thresholds induced by MMS and EMS and is the focus of research 235
in our group at present (see below). 236
5. Human variation in DNA repair and thresholds 237
Given that DNA repair appears to be centrally involved in 238
the existence of genotoxic thresholds, there is a potential for 239
population level variation in DNA repair genes which may alter 240
susceptibility to these genotoxins in the low dose region. Indeed, 241
it has previously been suggested that deﬁning a genotoxic thresh- 242
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Table 1
The link between polymorphisms in DNA repair genes involved in correcting
alkylatingagent-induceddamageandcancer risk. Todemonstrate the functional sig-
niﬁcance of DNA repair gene polymorphisms, published repair gene polymorphisms
linked to cancer susceptibility in molecular epidemiological studies are listed. The
list is by no means exhaustive, but merely reﬂects the link between DNA repair gene
variation and cancer risk.
Gene Polymorphism Cancer type
affected
Reference
XRCC1 −71 T/C Lung cancer
link
Vineis et al. (2009)
MGMT I143V Oesophageal
adenocarci-
noma
Doecke et al. (2008)
MGMT K178R Lung cancer Crosbie et al. (2008)
MGMT 56 C/T Colorectal
cancer
Ogino et al. (2007)
MGMT K178R Lung cancer Povey et al. (2007)
APEX I64V Lung cancer Zienolddiny et al. (2006)
MPG 8603 C/T, 12235 G/A Lung cancer Rusin et al. (1999)
old for a population might be impossible, due to genetic variation243
amongst individuals (Lutz, 2000). There is certainly the possibility244
that individuals will exist in a population who are more sensitive245
to a genotoxin due to possession of a DNA repair variant protein246
with lower than average efﬁciency. Table 1 summarises some of247
the polymorphisms known to be present in some of the DNA repair248
genes pertinent to alkylating agent-induced DNA damage. As can249
be see from Table 1, possession of some of these alleles is linked250
to increased risk to several cancer types, presumably due to lower251
DNA repair capacity. It is however, fair to say, that some conﬂicting252
evidence is present in the literature that requires some resolution.253
Tissue speciﬁcity of DNA repair gene expression is also a compli-254
cating factor here. Some of the polymorphisms noted in DNA repair255
genes have high allele frequencies, e.g. the MGMT I143V (which is256
in disequilibrium with K178R) is detected in up to 20–25% of some257
ethnic groups (reviewed in Pegg et al., 2007). Our own research has258
identiﬁed inter-individual variation in the gene expression levels259
of some genes involved in BER (Fig. 3) highlighting the heterogene-260
ity that is possible. Indeed in our studies (Fig. 3), there appeared261
Fig. 3. Gene expression levels for DNA repair genes (MPG, APEX, XRCC1) in blood
taken from healthy individuals. Expression levels (absolute mRNA levels, utilising a
cloned target for standard curve generation) show considerable variation (8–250-
fold) in the different individuals. Mpg shows least variation (8-fold), XRCC1 shows
125-fold variation, whilst APEX shows 250-fold variation in mRNA copy number.
Some variation may be induced due to environmental exposures (smoking status,
etc.) as well as host genetics. Data taken from paper recently submitted (Zaïr et al.,
submitted for publication).
Fig. 4. Hprt dose–responses for AHH1 and MT1 cells exposed to EMS are compared.
The dose–response for MT1 (repair deﬁcient cells) is shifted to the left suggesting
greater sensitivity to EMS. Indeed, the lowest observable effect level (LOEL) or the
ﬁrst dose giving a positive increase in mutation frequency is 1g/ml for MT1 cells
compare to 1.4g/ml for AHH1 cells.
to be an 8–250-fold variation in repair gene expression in the indi- 262
viduals monitored, although some of this variation could be due to 263
differences in environmental exposure and not due to genetic dif- 264
ferences (Zaïr et al., submitted for publication). Similar differences 265
in MGMT expression have also been noted, ranging from ∼8-fold 266
in lymphocytes to over a 100-fold in lung tissue (reviewed in Kaina 267
et al., 2007; Povey et al., 2007, respectively). 268
In extreme cases, heritable DNA repair deﬁciencies occur and 269
can be linked to syndromes which include a greater propensity to 270
certain cancer types (e.g.XerodermaPigmentosumandskincancer) 271
as well as neurological and developmental abnormalities (Cock- 272
aynes syndrome) and in some cases accelerated aging (progeria). 273
However, alleles leading to more subtle variations in repair efﬁ- 274
ciency (low penetrance), whilst being much more widespread are 275
likely to have a lesser impact on susceptibility. Indeed, it is often 276
the combination of alleles in a family of genes which will inﬂuence 277
overall susceptibility. Unpicking the haplotypes (combinations) of 278
DNA repair gene polymorphisms which inﬂuence susceptibility to 279
mutation and cancer is likely to be a complex process. An example 280
of a genedefect inDNArepair of higher penetrance is seen inHered- 281
itary Non-Polyposis Colorectal Cancer (HNPCC). HNPCC patients 282
inherit defects in one of 5 mismatch repair genes (MLH1, MSH2, 283
MSH6, PMS1, PMS2) and have increased risks of colorectal cancer 284
in particular, which are characterised by microsatellite instability, 285
due to lack ofMMR (Jascur and Boland, 2006). HNPCC is responsible 286
for ∼5% of colorectal cancers. Theoretically, if MMR were found to 287
be the keymediator of a threshold response to a genotoxin and safe 288
exposure levels in humans were calculated based on a threshold 289
dose inproﬁcientmodels, thenpatientswithHNPCCwouldbemore 290
susceptible tomutationandperhapscancer,whilst thegeneralpop- 291
ulation would be tolerant of exposure. In short, the threshold dose 292
calculated in this example would not necessarily apply for these 293
HNPCC individuals. The importance of DNA repair proﬁciency in 294
genotoxic thresholds is illustrated in Fig. 4. Fig. 4 displays EMS 295
induced hprt mutations in a repair deﬁcient cell line (MT1) com- 296
pared to the AHH1 cell line used in our previous studies (both being 297
lymphoblastoid cell lines). MT1 cells are known to be mismatch 298
repair deﬁcient, through loss of MSH6 (Szadkowski et al., 2005) 299
and hence may be more susceptible to alkylating agent-induced 300
mutagenesis. Clearly, the dose–response for the repair deﬁcient 301
cells is different to that of the DNA repair proﬁcient cells and might 302
suggest the impact that DNA repair proﬁciency has on genotoxic 303
dose–responses in populations. 304
Of course, the fact that MMR (and indeed other repair pro- 305
cesses) can unwittingly facilitate chromosome damage induction 306
(Armstrong and Galloway, 1997) complicates this view as efﬁcient 307
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MMR can drive chromosome damage and may represent a dou-308
ble edged sword in mutagenesis. Moreover, due to the overlapping309
speciﬁcity of the different DNA repair processes, other functional310
counterpart pathwaysmaywell compensate the reduced efﬁciency311
of one pathway. Therefore, failure of more than one pathway may312
be necessary to radically alter any population level threshold dose.313
Repair haplotypesmaybetter deﬁne susceptible individuals, allow-314
ing a better understanding of risk assessment in terms of exposure315
to genotoxic carcinogens. Furthermore, whilst it is accepted that316
MGMT and BER are centrally involved in the repair of alkylating317
agent-induced DNA damage, nucleotide excision repair (NER) can318
also contribute to this repair effort as shown by increased alkyla-319
tion sensitivity in NER deﬁcient cells (Op het Veld et al., 1997). This320
is particularly true for larger alkyl groups (ethyl, isopropyl) com-321
pared to methyl groups (Kaina et al., 2007). In the context of DNA322
repair heterogeneity and DNA repair deﬁciencies, it is interesting323
to note that inherited deﬁciencies of BER are rare, with BER deﬁ-324
cient embryos often being non-viable (Hasty et al., 2003). Hence,325
this shows theprimary importanceof someDNArepair pathways to326
normal development. Therefore whilst genotoxic thresholds based327
on BER processes may not have to contend with grossly suscepti-328
ble subpopulations, as gene deﬁciency is likely to be rare, subtle329
variations (polymorphisms) can still modulate BER efﬁciency in330
individuals (as shown in Table 1).331
Certainly, safety factors used in risk assessment need to take332
account of genetic variation in DNA repair genes (currently333
included for inter-individual variation in general), particularly334
when risk assessing a genotoxinwith a thresholdeddose–response.335
Mechanistic studies to better understand the biological basis for336
genotoxic thresholds are essential as they highlight the key pro-337
tective factors (like DNA repair) underlying the thresholds. In338
fact, before suggesting safe exposure limits to known genotoxins339
(thresholded or not), adequate characterisation of any protective340
mechanisms should be undertaken in order to inform the risk341
assessments necessary. The identiﬁcation of these protective pro-342
cesses and the genes involved, can then lead to the search for343
susceptible groups before setting safe exposure levels.344
6. Conclusion345
In conclusion, genotoxic thresholds have been demonstrated346
for two alkylating agents and are likely to be found for further347
chemicals in the coming years. DNA repair plays a major role in348
these threshold responses by removing the DNA damage/mutation349
induced at low levels. This DNA repair is often inducible at these350
low doses andmay be responsible for hormetic effects observed for351
EMS in vivo. As DNA repair gene polymorphisms exist and modu-352
late an individual’s repair proﬁciency, it is important to consider353
these polymorphisms (or combinations of polymorphisms) when354
calculating safety factors for safe exposure levels.355
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